Skip to main content
SpringerLink
Log in

Als Second-Line-Option punktet Axitinib

  • Literatur kompakt
  • Urogenitale Tumoren
  • Published:
Im Focus Onkologie Aims and scope

Große Frage beim fortgeschrittenem Nierenzellkarzinom: Wie geht es weiter nach Versagen der First-Line-Therapie? Wichtige Hinweise gibt die AXIS-Studie, in der zwei Tyrosinkinasehemmer zum direkten Vergleich antraten.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • Motzer RJ et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: Overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 2013;14(6):552–62.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Ulrike Wepner

Authors
  1. Ulrike Wepner
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wepner, U. Als Second-Line-Option punktet Axitinib. Im Focus Onkologie 16, 37 (2013). https://doi.org/10.1007/s15015-013-0576-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15015-013-0576-x

Search

Navigation